Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FKBP4 | Q02790 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547347 | 1.00 | CYP2D6 (0.49) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL8846065 | 1.00 | CYP2D6 (0.49) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL3821804 | 1.00 | CYP2D6 (0.49) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL29399931 | 1.00 | CYP2D6 (0.49) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL2719598 | 1.00 | CYP2D6 (0.49) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL15577086 | 1.00 | CYP2D6 (0.49) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL179200 | 0.98 | CYP2D6 (0.50) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL18268908 | 0.98 | CYP2D6 (0.50) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL3956872 | 0.93 | CA1 (0.57) | CYP2D6KMT2ACA1CA2CA4 | |
| SCHEMBL10704300 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134680-A1 | METHOD FOR PRODUCING CYCLIC ESTERS | BASF SE (DE) | 2018-05-17 | — | — | US | disclosed |
| US-8383834-B2 | Process for preparing unsaturated lactones | SYMRISE AG (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20090306411-A1 | PROCESS FOR PREPARING UNSATURATED LACTONES | SYMRISE GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2005113533-A9 | PROCESS FOR PREPARING UNSATURATED LACTONES | SYMRISE GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
| EP-1747211-B1 | PROCESS FOR PREPARING UNSATURATED LACTONES | SYMRISE GMBH & CO KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| EP-1747211-A1 | PROCESS FOR PREPARING UNSATURATED LACTONES | Akzo Nobel N.V. (NL) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005113533-A1 | PROCESS FOR PREPARING UNSATURATED LACTONES | SYMRISE GMBH & CO. KG (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134680-A1 | METHOD FOR PRODUCING CYCLIC ESTERS | OR51E2, HSD17B12, OR10J3 | CYP2D6 759/4885KMT2A 1411/4885CA1 294/4885 |
| US-20090306411-A1 | PROCESS FOR PREPARING UNSATURATED LACTONES | ALOX5, ALOX12, ALOX15 | CYP2D6 1056/4885KMT2A 2821/4885CA1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.